TD Cowen analyst Brendan Smith has maintained their bullish stance on DNLI stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Brendan Smith’s rating is based on Denali Therapeutics’ strategic advancements in their drug pipeline, particularly the recent submission of a Biologics License Application (BLA) for DNL310 under accelerated approval for treating mucopolysaccharidosis Type II (MPS II). The FDA’s acceptance of this filing could lead to a broad label and a potential launch next year, which is a significant milestone for the company.
Additionally, Denali is making progress with its deeper pipeline, expecting 1-2 new therapeutic candidates each year and anticipating global Phase 2 LUMA data for DNL151 in Parkinson’s Disease by 2026. The ongoing discussions with the FDA regarding an accelerated approval pathway for DNL126 in MPS IIIa, supported by promising proof-of-concept data, further bolster the company’s prospects. These factors collectively contribute to the Buy rating, reflecting confidence in Denali’s potential for growth and innovation in rare disease therapeutics.